Key result
Patients with MAFLD had a higher odds ratio for previous cardiovascular disease compared to those with NAFLD, whereas the risk of chronic kidney disease was higher in males with NAFLD.
Why the study?
MAFLD was proposed as a new definition emphasizing the metabolic aspects of NAFLD, prompting a direct comparison of cardiovascular and renal burden between the two conditions.
Does MAFLD carry a higher cardiovascular and renal burden compared to NAFLD in a Chinese population?
Cross-Sectional (n=12,183)
Does MAFLD carry a higher cardiovascular and renal burden compared to NAFLD in a Chinese population?
Odds Ratio: 1.5 (95% CI 1.22–1.85)
MAFLD is associated with a higher cardiovascular burden than NAFLD, whereas NAFLD may carry a higher renal burden in males.
May inform nuanced cardiometabolic risk stratification; leaves open prospective validation and causal inference.
Background/Purpose: Metabolic associated fatty liver disease (MAFLD) was proposed as a new definition to put emphasis on the metabolic aspects of nonalcoholic fatty liver disease (NAFLD). We aim to compare the cardiovascular and renal burden between MAFLD and NAFLD patients. Methods: 12183 participants were enrolled in East China. The cardiovascular burden (Framingham risk score and previous cardiovascular diseases (CVD)) and renal burden (eGFR and chronic kidney disease (CKD)) were measured. Results: The risk of hypertension, dyslipidemia, diabetes, overweight/obesity, and central obesity of MAFLD patients were higher than those of NAFLD. Patients with MAFLD have a similar or higher beta coefficients in Framingham risk score [beta (95%CI): male 0.062 (0.055,0.069) vs 0.041 (0.033,0.048); female 0.014 (0.012,0.016) vs 0.012 (0.01,0.014)], and higher odds ratio in previous CVD [odds ratio (95%CI): male 1.50 (1.22,1.85) vs 1.35 (1.1,1.66); female 1.58 (1.33,1.87) vs 1.45 (1.22,1.72)], compared with those with NAFLD. However, compared with males with MAFLD, the odds ratio of CKD was higher in those with NAFLD [eGFR: -2.731 (-3.422, -2.041) vs-3.578 (-4.268, -2.887). CKD: 1.44 (1.05,1.96) vs 1.56 (1.14,2.12)]. In female, CKD was only marginally associated with NAFLD [0.8 (0.62,1.02), P=0.075], but not MAFLD [0.87 (0.68,1.11), P=0.268]. Conclusions: Patients with MAFLD have a similar or higher risk of future and previous CVD compared with those with NAFLD, but the risk of CKD was higher in male with NAFLD.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2022) conducted a cross-sectional in Metabolic associated fatty liver disease (MAFLD) and Non-alcoholic fatty liver disease (NAFLD) (n=12,183). Metabolic associated fatty liver disease (MAFLD) vs. Non-alcoholic fatty liver disease (NAFLD) and healthy controls was evaluated on Previous cardiovascular disease (Male) (OR 1.50, 95% CI 1.22-1.85). Patients with MAFLD had a higher odds ratio for previous cardiovascular disease compared to those with NAFLD, whereas the risk of chronic kidney disease was higher in males with NAFLD.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: